Stay updated on GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial page.

Latest updates to the GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a new revision entry: Revision: v3.4.2. The older government funding status notice (Revision: v3.4.1) appears to have been removed.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH operating status. Updated the release notes from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check28 days agoChange DetectedThe page now includes a glossary toggle and updated metadata: 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', with the version tag updated to v3.4.0 (replacing v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision history updated: added v3.3.4 and removed v3.3.3; this appears to be a minor versioning update with no impact on study content or page functionality.SummaryDifference0.1%

- Check49 days agoChange DetectedThe screenshots indicate layout and styling updates to the Study Details page without altering core study content like eligibility criteria or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedNo significant changes detected in the Study Details page; content and core data appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial page.